Identity
- Security key
- 14810
- Ticker
- ENLV
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2014-07-31
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- ENLV
Detail
Enriched 2026-08-14 20:47
- Market cap
- $30,970,907.6
- Shares outstanding (class)
- 16,832,015
- Shares outstanding (weighted)
- 16,832,015
- SIC
- —
- Employees
- 34
- Location
- —
- Homepage
- https://www.enlivex.com
- Description
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Market cap and share counts drift.